A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
Public ClinicalTrials.gov record NCT05222802. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study to Evaluate the CNS-Penetrant EGFR/ERBB1 Inhibitor ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
* To evaluate the safety and tolerability of escalating doses of ERAS-801 in study participants with recurrent glioblastoma multiforme (GBM). * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-801. * To evaluate the antitumor activity of ERAS-801. * To evaluate the PK profile of ERAS-801.
Study identification
- NCT ID
- NCT05222802
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 52 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 24, 2022
- Primary completion
- Aug 30, 2025
- Completion
- Sep 29, 2025
- Last update posted
- Aug 16, 2025
2022 – 2025
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, Los Angeles | Los Angeles | California | 90095 | — |
| Miami Cancer Institute-Baptist Heath South Florida | Miami | Florida | 33176 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10022 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Sarah Cannon Research Institute (Tennessee Oncology) | Nashville | Tennessee | 37203 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Glioblastoma Multiforme trials
Other public records listing Glioblastoma Multiforme. Sorted by last update posted; newest first. Not a recommendation.
- NCT01837862: A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Active, not recruiting
- NCT04900792: A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma Active, not recruiting
- NCT05864976: Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning Recruiting
- NCT02177578: Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme Active, not recruiting
- NCT05120284: Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM) Active, not recruiting
- NCT06011109: Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05222802, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 16, 2025 · Synced Aug 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05222802 live on ClinicalTrials.gov.